Skip to main content
. 2020 Apr 2;10(2):117–121. doi: 10.4103/ijabmr.IJABMR_349_18

Table 2.

Distribution of cases based on estrogen receptor and progesterone receptor status in tumor mass

ER-PR status Number of patients (%)
ER+ and PR+ 23 (38.33)
ER+ and PR− 1 (1.67)
ER− and PR− 36 (60)
Total 60 (100)

ER: Estrogen receptor; PR: Progesterone receptor